Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.

Delve into the Amarin v. Hikma case in which the U.S. Supreme Court might settle the skinny label question once and for all.

Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 ...

From Dupixent to Tezspire and verekitug, explore emerging sinusitis treatments and the race to improve chronic rhinosinusitis care.

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

Based in Switzerland, Alentis Therapeutics is a clinical-stage biotech company developing first-in-class therapies that target Claudin-1 (CLDN1), a tight-junction protein abnormally expressed in ...

Last year, we took a look at the biotech trends that we thought would shape 2024. Now, as we enter the new year, the biotech industry is continuing to evolve at a rapid pace, and 2025 is shaping up to ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech ...